Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.~* Male or female, age above or equal to 18 years at the time of signing informed consent.~For Algeria only: Male or female, age above or equal to 19 years at the time of signing informed consent.~For Taiwan only: Male or female, age above or equal to 20 years at the time of signing informed consent~* Diagnosed with type 2 diabetes mellitus 60 days or more prior to day of screening.~* HbA1c between 7.0-10.5% (53-91 mmol/mol) (both inclusive).~* Stable daily dose of metformin (equal to or above 1500 mg or maximum tolerated dose as documented in the subject medical record) 60 days or more prior to day of screening~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method (adequate contraceptive measure as required by local regulation or practice).~* Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid carcinoma (MTC). Family is defined as a first degree relative.~* History or presence of pancreatitis (acute or chronic).~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).~* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening and randomisation.~* Subjects presently classified as being in New York Heart Association (NYHA) Class IV.~* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.~* Renal impairment measured as estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m\^2 as per Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI).~* Subjects with alanine aminotransferase (ALT) above 2.5 x upper limit of the normal (ULN).~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation. Fundus examination without dilation is only allowed if the digital camera used for fundus photography has this feature.~* Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ is allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral semaglutide 3 mg and placebo (sitagliptin) (Type: EXPERIMENTAL): Oral semaglutide tablets 3 mg and sitagliptin placebo tablets for 26 weeks
- Oral semaglutide 7 mg and placebo (sitagliptin) (Type: EXPERIMENTAL): Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 4 weeks, after which the target dose of 7 mg is taken for 22 weeks
- Oral semaglutide 14 mg and placebo (sitagliptin) (Type: EXPERIMENTAL): Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 8 weeks, after which the target dose of 14 mg is taken for 18 weeks
- Sitagliptin 100 mg and placebo (oral semaglutide) (Type: EXPERIMENTAL): Sitagliptin tablets and oral semaglutide placebo tablets for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).